Karyopharm Therapeutics Investor Presentation — September 2021

Document content

1 ©2021 KARYOPHARM THERAPEUTICS INC.

Novel Cancer Therapies

September 20212 ©2021 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information

This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding Karyopharm’s

guidance onitsexpected cash runway ;expectations andplans relating toXPOVIO forthetreatment ofadult patients with relapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-cell

lymphoma andother hematologic malignancies andsolid tumors ;commercialization ofXPOVIO oranyofitsdrug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview and

potential approval ofselinexor by,regulatory authorities, including theCompany’s regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions by

regulatory authorities andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;andthetherapeutic potential ofandpotential clinical development

plans forKaryopharm's drug candidates, especially selinexor .Such statements aresubject tonumerous important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay

cause actual events orresults todiffer materially from Karyopharm's current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators will

grant confirmatory approval intheEuropean Union based ontheBOSTON study inadult patients with multiple myeloma ;orthatanyofKaryopharm’s drug candidates, including selinexor andeltanexor, will